<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041920</url>
  </required_header>
  <id_info>
    <org_study_id>FMTN-I-111</org_study_id>
    <nct_id>NCT05041920</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects</brief_title>
  <official_title>A Single-centre, Single-arm, Open-label and Fixed-sequence Study to Evaluate the Effect of Omeprazole on Pharmacokinetics of Famitinib Malate in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the effect of omeprazole on the pharmacokinetics of&#xD;
      famitinib malate in healthy adult subjects.&#xD;
&#xD;
      The secondary objective is to evaluate the safety after famitinib malate alone or combined&#xD;
      administration with omeprazole in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">October 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single-arm, open-label and fixed-sequence drug interaction study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>day 1 to day 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>day 1 to day 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞(if applicable)</measure>
    <time_frame>day 1 to day 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>day 1 to day 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>day 1 to day 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>day 1 to day 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>day 1 to day 23</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events/serious adverse events</measure>
    <time_frame>from ICF signing date to approximate day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will have only one study group in a fixed-sequence type of design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>famitinib、omeprazole</intervention_name>
    <description>famitinib malate, 25 mg on study day 1; omeprazole, 40 mg, qd on study day 10-14, 16-22; famotine malate together with omeprazole, on study day 15.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants should sign the informed consent before the study, and fully understand&#xD;
             the content, process and possible adverse reactions of the study;&#xD;
&#xD;
          2. Capable to complete the study according to the requirements of study protocol;&#xD;
&#xD;
          3. Healthy male and female subjects aged between 18 and 45 (inclusive) at the time of&#xD;
             signing the informed consent, of which no less than 1/3 are female subjects;&#xD;
&#xD;
          4. Participants should have no fertility plan from signing the informed consent until 6&#xD;
             months after the last medication, take effective contraceptive measures voluntarily&#xD;
             and have no sperm donation plan. The serum HCG test of fertile women must be negative&#xD;
             before Screening;&#xD;
&#xD;
          5. Body weight ≥ 50.0 kg for men and body weight ≥ 45.0 kg for women, and body mass index&#xD;
             (BMI) within the range of 19.0 to 28.0 kg /m2 (inclusive);&#xD;
&#xD;
          6. Creatinine clearance (CLCr) ≥80 mL/min, and creatinine is less than or equal to the&#xD;
             upper limit of normal value.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who donated blood or suffered blood loss ≥400 mL within 3 months prior to&#xD;
             Screening, donated blood or suffered blood loss ≥200 mL within 1 month prior to&#xD;
             Screening, or received blood transfusion;&#xD;
&#xD;
          2. Allergic constitution, including a history of severe drug/food allergy; Any history of&#xD;
             allergy to famitinib malate capsules or omeprazole magnesium enteric-coated tablets;&#xD;
&#xD;
          3. Any history of drug abuse, positive results for alcohol, nicotine or drugs at&#xD;
             Screening;&#xD;
&#xD;
          4. Those who have heavy smokers and alcoholic will not be able to prohibit smoking and&#xD;
             alcohol during the trial;&#xD;
&#xD;
          5. Any history of dysphagia or any gastrointestinal disease that affects drug absorption;&#xD;
&#xD;
          6. Those who have any uncontrolled peptic ulcer, colitis, pancreatitis, etc.;&#xD;
&#xD;
          7. Those who have received any operation within 6 months before Screening; Previous&#xD;
             surgery affecting gastrointestinal absorption (including gastrectomy, intestinal&#xD;
             resection, gastric contraction surgery, etc.);&#xD;
&#xD;
          8. Subjects with any clinically significant acute disease occurring within 1 month prior&#xD;
             to Screening;&#xD;
&#xD;
          9. QTcF&gt;470 msec for women or &gt;450 msec for men;&#xD;
&#xD;
         10. Any pre-existing chronic or severe medical history of nervous system, cardiovascular&#xD;
             system, urinary system, digestive system, respiratory system, metabolism, and&#xD;
             musculoskeletal system;&#xD;
&#xD;
         11. Participation in any clinical trial within 3 months before Screening;&#xD;
&#xD;
         12. Those who took any other drugs that affect liver metabolism within 28 days prior to&#xD;
             taking the investigational drug;&#xD;
&#xD;
         13. Those who took any prescription or non-prescription drugs, any vitamin products or&#xD;
             herbal medicine within 14 days prior to receiving the investigational drug;&#xD;
&#xD;
         14. Abnormal vital signs at Screening;&#xD;
&#xD;
         15. Clinical laboratory tests, infectious disease screening, 12-lead electrocardiogram,&#xD;
             abdominal B ultrasound, X-ray or CT examination with abnormalities and clinical&#xD;
             significance;&#xD;
&#xD;
         16. Consumption of grapefruit or grapefruit products, caffeine, or xanthine foods or&#xD;
             beverages within 48 hours prior to taking the investigational drug; Strenuous&#xD;
             exercise, or other factors affecting drug absorption, distribution, metabolism,&#xD;
             excretion, etc.;&#xD;
&#xD;
         17. Lactating women;&#xD;
&#xD;
         18. History of injection needle or blood fainting, those who have difficulty in blood&#xD;
             collection or cannot tolerate venepuncture blood collection; Those who cannot accept a&#xD;
             uniform diet;&#xD;
&#xD;
         19. Subjects with other factors unsuitable to participate in the study considered by the&#xD;
             researcher or subjects withdraw from the study due to their own reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongda Hospital, Affiliated to Southest University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

